Navigation Links
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Date:1/12/2009

p>

Bradbury added, "Our priorities are clear: Grow BYETTA and SYMLIN revenue, submit the NDA for exenatide once weekly and maintain an unwavering focus on managing expenses to achieve positive cash flow by the end of 2010."

A recording of the presentation is accessible through Amylin's corporate Web site, located at www.amylin.com.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Amylin's actual results could differ materially from those discussed due to a number of risks and uncertainties, including the risks that: BYETTA and SYMLIN and the revenues generated from these products may be affected by competition, unexpected new data, and safety and technical issues; clinical trials, including those mentioned in this press release, not being completed in a timely manner, confirming previous results, or achieving the intended clinical endpoints; label expansion requests or NDA filings, including those mentioned in this press release, not being submitted in a timely manner; regulatory approvals being delayed or not received; updates to the BYETTA label not being finalized in a timely m
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 Nematicide ... kill nematodes. Nematodes are microscopic parasitic roundworms, found ... and inside other plants and animals. Nematicides have ... or other properties promoting migration through the soil. ... than 1,000 plant-parasitic nematodes. With more than 10,000 ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
(Date:9/30/2014)... BALTIMORE and ROCKVILLE, Md., Sept. 30, 2014 /PRNewswire/ ... private-public partnership focusing on commercializing market-relevant biohealth innovations and ... Maryland , announced today that venture capitalist, ... as a strategic advisor. Dr. Fernandez will be a ... Gap Fund, which will provide up to $50 million ...
(Date:9/30/2014)... Lyme Research Alliance (LRA), the nation’s ... universities, today announced the awarding of seven grants worth ... cure for Lyme and other tick-borne diseases. , ... its history—over 20 grant proposals—a 100 percent increase from ... receive so many solid applications from talented scientists this ...
Breaking Biology Technology:Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... Area Technical College is launching a major effort to ... colleges and high schools. The initiative will feature new ... better prepare qualified technicians to work in the fast ... Foundation (NSF) grant - the second such grant MATC ...
... - Alfalight, Inc. , a Madison-based manufacturer ... markets, has been awarded $1.4 million in funding for ... program, sponsored by the Defense Advanced Research Projects ... is to increase a laser's power conversion efficiency -- ...
... Days of summer. Business slows. Indeed, in Europe, where I ... of suspended animation that will last until the first of ... attention. Work's grasp weakens. , ,Or does it? , ,After ... Monday morning mountain in my inbox and a to-do list ...
Cached Biology Technology:Alfalight garners $1.4 million defense funding for diode program 2Leaving it all behind 2
(Date:9/30/2014)... environment on Earth, but when the climate changes and ... limit. The amount of time needed to adjust to ... cope in the future, reveals a new study from ... scientific journal Proceedings of the Royal Society B ... levels of greenhouse gases in the atmosphere. The greenhouse ...
(Date:9/30/2014)... goes wrong with your muscles because of age, disease or ... is. That,s where a new research report published in the ... comes in. In the report, a team of scientists ... help scientists "see" which genes are active in an organ ... activity and that men have approximately 400 more active genes ...
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... HARBOR, N.Y. Many proteins do not function ... associate to form larger structures called protein complexes. ... ( www.cshprotocols.org/TOCs/toc5_09.dtl ) features a set of methods ... An additional featured article details the generation of viral ...
... Society (ACS) Weekly PressPac from the Office of ... peer-reviewed journals and Chemical & Engineering News ... American Chemical Society as the source for this ... ARTICLE #1 FOR IMMEDIATE RELEASE Gene ...
... the introduction of genetic material into a patient,s cells resulting ... years, it has been shown that gene therapy is a ... for which there is no attractive alternative therapy. Gene ... other diseases that affect heart, brain and even for cancer. ...
Cached Biology News:Protein analysis methods, viral vectors featured in Cold Spring Harbor Protocols 2American Chemical Society's weekly PressPac -- April 29, 2009 2American Chemical Society's weekly PressPac -- April 29, 2009 3American Chemical Society's weekly PressPac -- April 29, 2009 4American Chemical Society's weekly PressPac -- April 29, 2009 5American Chemical Society's weekly PressPac -- April 29, 2009 6Moving gene therapy forward with mobile DNA 2